December 2024

Maternal Sepsis

Clinical guidance

|  |
| --- |
|  |
| To receive this publication in an accessible format email Safer Care Victoria <info@safercare.vic.gov.au>Authorised and published by the Victorian Government, 1 Treasury Place, Melbourne.© State of Victoria, Australia, Safer Care Victoria, *Month* 2024ISBN 978-1-76131-585-5Available at the [Safer Care Victoria website](https://www.safercare.vic.gov.au) <https://[www.safercare.vic](http://www.safercare.vic).gov.au>Victoria State Government |

**Contents**

[Key messages 4](#_Toc184299944)

[Acknowledgement 4](#_Toc184299945)

[Consumer Engagement Statement 4](#_Toc184299946)

[Definitions/abbreviations 4](#_Toc184299947)

[Local health service adaptation 5](#_Toc184299948)

[Background 5](#_Toc184299949)

[Common causes of sepsis in this cohort are: 5](#_Toc184299950)

[Recognising sepsis 6](#_Toc184299951)

[Initial sepsis screen 7](#_Toc184299952)

[Recognise 7](#_Toc184299953)

[Respond 7](#_Toc184299954)

[Confirmation of sepsis 8](#_Toc184299955)

[Ongoing management 9](#_Toc184299956)

[Antibiotic prescribing and administration 9](#_Toc184299957)

[Additional considerations 10](#_Toc184299958)

[Summary flow chart 10](#_Toc184299959)

[Call for help flowchart 11](#_Toc184299960)

[Table 1: Antibiotic recommendations: Unknown source of infection or chorioamnionitis 12](#_Toc184299961)

[Table 2: Additional antibiotic considerations, including Group A Streptococcus 13](#_Toc184299962)

[Table 3: Rapid antibiotic administration advice 13](#_Toc184299963)

[Table 4: White cell count in pregnancy – normal range: a reference table for clinicians 13](#_Toc184299964)

[References 14](#_Toc184299965)

[Citation 15](#_Toc184299966)

[Acknowledgement 15](#_Toc184299967)

[MATERNAL SEPSIS PATHWAY 16](#_Toc184299968)

**Key messages**

* Sepsis is one of the leading causes of maternal deaths in Australia.1
* This guideline provides an evidence-based guide for clinical staff to identify and manage suspected or confirmed sepsis in pregnant women, from 16 weeks gestation to around 2 weeks postpartum.
* It focuses on ensuring prompt diagnosis, appropriate investigations and antibiotic therapy.
* It has been developed to guide initial diagnosis and management, for health services to adapt as required.

**Acknowledgement**

1. This guidance uses the terms ‘woman’ and ‘mother,’ which are intended to be inclusive of anyone who may use other self-identifying terms and aims to encompass all for whom this guidance is relevant.

**Consumer Engagement Statement**

All interactions between health care staff with consumers (women, mothers, patients, carers and families) should be undertaken with respect, dignity, empathy, honesty and compassion.  ​

​

Health care staff should actively seek and support consumer participation and collaboration to empower them as equal partners in their care.

**Definitions/abbreviations**

| **Term** | **Definition** |
| --- | --- |
| CPOs (Carbapenemase Producing Organisms) | Bacteria that have developed resistance to several antibiotics, including carbapenems |
| CSU | Catheter specimen of urine |
| DBP | Diastolic blood pressure |
| ESBL (extended spectrum beta lactamase) | An enzyme found in some strains of bacteria. ESBL-producing bacteria can't be killed by many antibiotics such as penicillins and some cephalosporins.  |
| FiO2  | Fraction of inspired oxygen |
| Group A streptococcus (GAS) infection | Also known as *Streptococcus pyogenes*  |
| HVS | High vaginal swab |
| LVS | Low vaginal swab |
| MAP | Mean arterial blood pressureDiastolic BP + 1/3 (systolic BP – diastolic BP) |
| MROs (multi-resistant organisms) | Organisms that are resistant to some antimicrobials |
| MRSA (methicillin-resistant *Staphylococcus aureus)* | *Staphylococcus aureus* that is resistant to methicillin/ flucloxacillin  |
| MSU | Midstream urine |
| PaO2  | Partial pressure of oxygen (assessed with arterial blood gas) |
| Puerperal sepsis | Peripartum sepsis resulting from the genitourinary tract  |
| SBP  | Systolic blood pressure |
| Sepsis  | A life-threatening organ dysfunction caused by a dysregulated host response to infection. A diagnosis of sepsis is considered in any patient with an acute illness or clinical deterioration that may be due to infection6 Sepsis is a life-threatening condition |
| Septic shock | Septic shock is defined as ‘a subset of sepsis in which the underlying circulatory, cellular and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone6 |

## Local health service adaptation

1. The specific areas that may need local adaptation are:
* Pathways of escalation, including the availability of senior staff, of expertise in infectious diseases and when intra- or inter-hospital transfer is required.
* Choice of antibiotics depending on local conditions – this is particularly relevant for aminoglycosides. Regimens have been provided for gentamicin, tobramycin and amikacin.

**Background**

1. Sepsis can be a life-threatening condition that requires a time critical response. The effects can be life-changing, leading to lasting maternal illness affecting the woman’s passage to motherhood, the establishment of breastfeeding and her ongoing connection to her baby.
2. Clinicians should provide open and consistent communication with the woman (when feasible) and her support people.

## Common causes of sepsis in this cohort are:

* Septic abortion, chorioamnionitis, pneumonia/influenza, pyelonephritis, wound infection, mastitis, endometritis. (with or without retained products of conception)
* *E. coli* is the most common cause of maternal bacterial infection. The most frequent cause of maternal death from sepsis is infection with *Group A streptococcus (GAS) species*. Invasive GAS infection typically manifests as sepsis, endomyometritis, cellulitis, necrotising fasciitis, or toxic shock syndrome.

**Recognising sepsis**

1. Recognition of sepsis is a critical first step in appropriate assessment and management, regardless of the care setting, in community or a hospital. Consider sepsis in all patients with acute illness or physiological deterioration who may have an infection and ask the question ‘could it be sepsis?’ as part of regular clinical assessments.
2. In pregnancy, diagnosis may be more difficult because physiological changes associated with pregnancy and/or labour may mimic the signs of sepsis (e.g. elevated heart rate and respiratory rate, lower blood pressure, raised white blood cell count, increased lactate during labour).
3. Risk factors that may assist with the early recognition of maternal sepsis could include bleeding in pregnancy, miscarriage, prolonged rupture of membranes, prolonged labour, retained products of conception and fetal tachycardia.
4. This guidance utilises a modification of the California Maternal Quality Care Collaborative (CMQCC) 2020 screening criteria.2 The CMQCC reports fewer missed cases with fewer false positives, compared with other screening tools.

**Initial sepsis screen**

## Recognise

1. **Consider sepsis if there is evidence of an infection and the woman has two or more of the following:**

| **Site of concern** | **Signs or symptoms** |
| --- | --- |
| **Fevers and rigors** | * self-reported or observed
 |
| **Neurological** | * altered conscious state
* headache
* neck stiffness
* agitation
 |
| **Poor peripheral perfusion** | * cool peripheries
* delayed capillary refill time or mottled skin
 |
| **Chest** | * cough
* shortness of breath
 |
| **Abdomen** | * pain/tenderness
* peritonism
* diarrhoea
* vomiting
 |
| **Malodorous vaginal discharge** | * self-reported or detected
 |
| **Urine** | * dysuria
* frequency
* flank pain
 |
| **Skin and soft tissue** | * cellulitis
* mastitis
* wound erythema or discharge
 |
| **Line insertion sites** | * erythema
* pain
* swelling
* discharge
 |
| **Blood pressure** | * MAP < 65mmHg
 |
| **Two or more of the following** | * temperature < 36°C or > 38°C
* respiratory rate > 24 per minute sustained for 15 minutes
* heart rate > 110 sustained for 15 minutes
* WCC 15 × 109 or < 4 × 109 or > 10% immature neutrophils (bands) (Diagnosis of sepsis should not be delayed while waiting for results. A white blood cell count that has been obtained within 24 hours can be used for the initial screen
 |

1. **If the initial sepsis screen is positive and there is clinical suspicion or evidence of infection, start treatment.**

## Respond

**Rapid response - most tasks will need to be carried out concurrently**

| 1. **Oxygen**
 | * Continuous oximetry
* Administer supplementary oxygen to maintain SpO2 > 95%
 |
| --- | --- |
| **IV access** | * Insert 2 × large bore peripheral cannula
 |
| **Investigations** | * FBE, U&Es, LFTs, INR, APTT
* Venous blood gas for lactate
* Two sets of anaerobic and aerobic blood cultures
 |
| **Observations** | * Heart rate and blood pressure every 15 minutes for the first hour, then according to local guidance depending on degree of physiological disturbance
* Document on Maternal Observations and Response Chart (MORC)
 |
| **Antibiotics** | * Complete intravenous antibiotic administration within 60 minutes of presentation
* Refer to [Table 1](#_Table_1:_Antibiotic) for antibiotic recommendations where source is chorioamnionitis or unknown
* Refer to Therapeutic Guidelines – Antibiotic where the source of infection is known
* Refer to [Table 2](#_Table_2:_Additional) for additional antibiotic considerations
* Refer to [Table 3](#_Table_3:_Rapid) for administration guidance
 |
| **Source screening*****Do not delay antibiotic treatment for culture collection.*** | * Investigations as determined by clinical assessment of likely source of infection:
* midstream urine (MSU)/catheter specimen of urine (CSU)
* high vaginal (HVS) / low vaginal (LVS) / endocervical swab for microscopy/culture/sensitivities (MCS)
* sputum MCS
* chest x-ray
* nasal/ throat swabs for extended panel respiratory viruses multiplex PCR, including COVID-19
* wound swab for MCS
* cultures from lumens of central lines
* stool testing for faecal multiplex PCR including C. difficile
* breast milk MCS
 |
| **Fluid management** | * Fluid resuscitation if systolic BP < 90 mmHg (or if lactate ≥ 2 mmol/L in the absence of labour)
* stat fluid bolus of 500 mL of IV crystalloid, i.e. 0.9% sodium chloride; then further 500 mL STAT if required. Be aware of comorbidities, e.g. cardiac or respiratory disease, that may make fluid overload more likely
* monitor for fluid overload
* escalate if no improvement in SBP after 1L of IV fluid.
* insert IDC with hourly measure
* monitor urine output hourly
* escalate if urine output < 20 mL/hr and/or 0.5mL/kg/hour
 |
| **Fetal considerations** | * Consider fetal surveillance if appropriate for the gestation of the pregnancy.
* Consider urgent birth if chorioamnionitis is suspected. At pre- or peri-viable gestations, delivery may be required for maternal wellbeing.
* If pre-term birth is likely, give corticosteroids according to local protocol. Maternal health is the priority rather than fetal lung maturity.
* Consider contacting PIPER for further advice on 1300 137 650
 |
| **Escalate** | * Involve senior staff – consider anaesthetics, medical teams, ICU, ED or ARV in line with local escalation procedures
* Consider transfer to a higher acuity ward or a higher maternity capability level service
 |

**Confirmation of sepsis**

1. **Further tests:** These tests/observations may be useful for considering care setting including transfer to a higher level of care or downgrading care. They will not be required for all women and should be undertaken in consultation with senior clinicians.

| **Measure**  | **Criteria (any one is diagnostic)** |
| --- | --- |
| **Respiration****PaO/FiO2** | * Acute respiratory failure as evidenced by acute need for invasive or non-invasive mechanical ventilation **or**
* PaO2/FiO2 < 300
 |
| **Coagulation (FBE, INR, APTT)** | * Platelets < 100 × 109/L **or**
* INR > 1.5 **or**
* PTT > 60 seconds < 100
 |
| **Liver (LFT)** | * Bilirubin > 30 μmol/L
 |
| **Cardiovascular** | Persistent hypotension (SBP < 85 mmHg) after fluid administration **or** MAP < 65 mmHg **Or** BP > 40 mmHg decrease in SBP |
| **Renal (U&E, urine output)** | * Serum creatinine > 100 μmol/L **or**
* Doubling of creatinine **or**
* Urine output < 20mL/hr and/or 0.5 mL/kg/hour (for 2 hours)
 |
| **Mental status assessment**  | * Agitation, confusion, or unresponsiveness
 |
| **Lactate** | * ≥ 2 mmol/L in the absence of labour
 |

**Ongoing management**

|  |  |
| --- | --- |
| **Reassess management** | * The woman requires close observation and re-evaluation
* Perform targeted history, examination and investigations to elicit cause of sepsis
* Review any modifications to reportable observations / MET criteria
* Inform senior staff and document discussion and assessment in medical records
* Ensure clinical handover includes sepsis history
* Review all antibiotics and de-escalate as appropriate.
 |
| **General measures** | * Consider need for anticoagulation
* Consider use of antipyretics
* Source control
 |

**Antibiotic prescribing and administration**

1. 1. **Prescribe** antibiotics
* Unknown source or chorioamnionitis These regimens are for **initial** intravenous doses for **sepsis/septic shock** and should be used for all women to minimise delays to administration ([Table 1](#Table1)).
* Known source: According to Therapeutic Guidelines3 or local, evidence-based guidelines.
* Also consider additional risk factors ([Table 2](#Table2)).
1. 2. **Administer** complete dose of antibiotics within 60 minutes of consideration of sepsis
* In the setting of a **critically unwell woman**, antibiotics can safely be given at faster rates than in usual practice and multiple antibiotics can be given concurrently, intravenously at different sites4 ([Table 3](#Table3)). Hospital protocols will dictate administration method of choice – e.g. syringe pump, slow push.
1. 3. **Seek pharmacist/infectious diseases advice** for ongoing maintenance dosing, including in the setting of renal impairment or obesity.
2. **4. Aminoglycosides:**
* Each hospital should choose a single agent from gentamicin, amikacin or tobramycin, in consultation with local expertise and then use that agent consistently ([Table 1](#Table1)).

**Additional considerations**

* Abnormal temperature and elevated heart rate may be the most common combination, however not all women with sepsis will have a fever at ≥ 38.0°C.
* Maternal corticosteroid administration often increases the white blood cell count, but the suspicion for infection should not be discounted without further evaluation. White blood cell values peak 24 hours after administration and return close to baseline values by 96 hours after administration.
* Support for ongoing breastfeeding or assistance with expressing of breast milk, in keeping with the woman’s wishes, should be offered.
* Women and their families should be informed that they have/had a diagnosis of sepsis and provided with appropriate opportunities for information provision and debriefing.

**Summary flow chart**

|  |
| --- |
| **Think sepsis if any 2 of the following are present, plus a clinical suspicion of sepsis:*** Temperature < 36oC or ≥ 38oC
* Heart rate > 110 for at least 15 minutes
* Respiratory rate > 24 per minute for at least 15 minutes
* White cell count > 15 × 109 or < 4 × 109
* MAP < 65 mmHg
 |

**Call for help flowchart**

**Table 1: Antibiotic recommendations: Unknown source of infection or chorioamnionitis**

| 1. Indication
 | 1. No penicillin allergy
 | 1. Non-severe penicillin hypersensitivity (No features of immediate or delayed severe hypersensitivity e.g., childhood rash, nausea or vomiting)
 | Severe penicillin hypersensitivity1. Includes immediate hypersensitivity with urticarial, angioedema, hypotension, collapse, anaphylaxis, or delayed hypersensitivity with severe cutaneous reaction e.g. DRESS or SJS
 |
| --- | --- | --- | --- |
| Community-acquired sepsis[Infection present before admission]  | \*aminoglycoside IVTHENflucloxacillin 2g IV, 4-hourlyPLUSmetronidazole 500mg IV, 12-hourly | \*aminoglycoside IVTHENcefazolin 2g IV, 6-hourly PLUSmetronidazole 500mg IV, 12-hourly | \*aminoglycoside IV THENmetronidazole 500 mg, IV, 12 hourly PLUS vancomycin 25mg/kg loading dose, then 1.5g IV 12-hourly Check level before the 4th dose |
| Hospital-acquired sepsis[Infection acquired as a direct or indirect result of healthcare] | piperacillin/ tazobactam 4.5g IV, 6-hourly | \*aminoglycoside IVTHENcefazolin 2g IV, 6-hourly PLUSmetronidazole 500mg IV, 12-hourly  | \*aminoglycoside IV THENvancomycin IV 25mg/kg loading dose, then 1.5g IV 12-hourly. Check level before the 4th dosePLUS metronidazole 500mg, IV, 12 hourly |
| Chorioamnionitis | \*aminoglycoside IVTHENamoxicillin 2g IV 6-hourlyPLUS metronidazole 500 mg IV 12-hourly | \*aminoglycoside IVTHENcefazolin 2g IV, 6-hourly PLUSmetronidazole 500mg IV 12-hourly | \*aminoglycoside IV PLUS metronidazole 500 mg IV, 12 hourly PLUS vancomycin 25mg/kg loading dose, then 1.5g IV 12-hourly Check level before the 4th dose |

1. **For women with allergies to any of the antibiotics above, escalate for specialist advice.**
2. **\*Aminoglycoside**:
3. Each hospital should choose their primary aminoglycoside in accordance with local susceptibility patterns and in conjunction with regional partners and local expertise. Dosing is based on estimated or measured weight, rather than ideal body weight. (adjusted body weight for women with a BMI>30)
4. Use the same dose regardless of renal function for initial dose.

Gentamicin – initial dose 7 mg/kg for septic shock to maximum 600 mg (Routinely used in pregnancy)

Amikacin – 28 mg/kg to maximum 2,800 mg

Tobramycin 7 mg/kg to maximum 600 mg

**Table 2: Additional antibiotic considerations, including Group A Streptococcus**

| **Indications**  | **Antibiotic**  |
| --- | --- |
| Septic shock: persisting hypotension despite resuscitation | ADD vancomycin 25mg/kg loading dose, then 1.5g IV 12-hourly (if at risk of MRSA colonisation and/or presence of lines) |
| Group A StreptococcusContact with GAS infection caseToxic shock | ADD clindamycin 600mg IV 8 hourly CONSIDER IV immunoglobulin 1-2 g/kg IV (with ID consultation) |
| Suspected Neisseria meningitidis infection, **or** suspected CNS infection | ADD ceftriaxone 2g, IV, 12 hourly  |
| Woman with prior history of multi-resistant Gram-negative colonisation – e.g. CPOs, ESBLs, multi-resistant organisms (MRO), **or**Overseas hospitalisation or travel in the previous 6 months  | REPLACE all empiric antibiotics with single agent meropenem 2g, IV, 8 hourly |
| MRSA carrier: Based on previous swabs/ cultures or residence in NT, remote communities in FNQ or northern WA or recent incarceration, or recent prolonged hospital stay | ADD vancomycin 25mg/kg loading dose, then 1.5g IV, 12-hourly  |

**Table 3: Rapid antibiotic administration advice**

| **Antibiotic** | **Administration instructions**  |
| --- | --- |
| Amoxycillin | 1g with 20 mL water for injection over 3–4 minutes (2x1g amoxicillin vials are needed) |
| Clindamycin | Dilute 600 mg in 50 mL sodium chloride 0.9% and infuse over 20 minutes |
| Ceftriaxone | 2g with 40 mL water for injection and infuse over 5 minutes  |
| Cefazolin | 2g with 19 mL water for injection and infuse over 5 minutes |
| Flucloxacillin | 2g with 40 mL water for injection and infuse over 6–8 minutes |
| Gentamicin | Dilute with 20 mL sodium chloride 0.9% and infuse over 3–5 minutes |
| Metronidazole | Infuse over 20 minutes |
| Piperacillin/ tazobactam | 4.5g with 20 mL water for injection and infuse over 5 minutes |
| Vancomycin | 500 mg with 10 mL water for injection and 1g with 20 mL water for injection to make a concentration of 50mg/mL. Dilute to 5 mg/mL with sodium chloride 0.9%, i.e. dilute 1g to at least 200 mL.\* 1g may be infused over 1 hour, 1.5g over 1.5 hours and 2g over 2 hours.\* If fluid restriction, max concentration 10 mg/mL, i.e. dilute 1g in 100 mL |

**Table 4: White cell count in pregnancy – normal range: a reference table for clinicians**

|  |  |
| --- | --- |
| Non pregnant adult5. | 3.5–9.1 × 103 mm3 |
| First trimester | 5.7–13.6 × 103 mm3 |
| Second trimester | 5.6–14.8 × 103 mm3 |
| Third trimester  | 5.9–16.9 × 103 mm3 |

**References**

1. Australian Institute of Health and Welfare. Maternal deaths in Australia. Cat. no. PER 99. 2020 [cited 2024 May 01]. Available from: <https://www.aihw.gov.au/reports/mothers-babies/maternal-deaths-australia>
2. Gibbs R, Bauer M, et al. Improving Diagnosis and Treatment of Maternal Sepsis: A Quality Improvement Toolkit. [Internet]. Stanford CA., California Maternal Quality Care Collaborative; 2020 [cited 2024 May 7]. Available from: <https://www.cmqcc.org/resources-toolkits/toolkits/improving-diagnosis-and-treatment-maternal-sepsis>
3. Therapeutic Guidelines: Antibiotic. Available from: <https://tgldcdp.tg.org.au/guideLine?guidelinePage=Antibiotic&frompage=etgcomplete>
4. Australian Injectable Drugs Handbook (AIDH) 9th Edition. Available from: https://www.shpa.org.au/publications-resources/aidh
5. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and Laboratory Studies: A Reference Table for Clinicians. Obstetrics & Gynecology. 2009 Dec;114(6):1326-1331. DOI: 10.1097/AOG.0b013e3181c2bde8.
6. Australian Commission on Safety and Quality in Health Care. Sepsis Clinical Care Standard. Sydney: ACSQHC; 2022. Available from: <https://www.safetyandquality.gov.au/publications-and-resources/resource-library/sepsis-clinical-care-standard-2022>

**Additional resources**

* Australian Commission on Safety and Quality in Health Care. Review of trigger tools to support the early identification of sepsis in healthcare settings. Sydney: ACSQHC; 2021. Available from: <https://www.safetyandquality.gov.au/publications-and-resources/resource-library/review-trigger-tools-support-early-identification-sepsis-healthcare-settings>.
* Bowyer L, Cutts BA, Barrett HL, Bein K, Crozier TM, Gehlert J, Giles ML, Hocking J, Lowe S, Lust K, Makris A, et al. SOMANZ position statement for the investigation and management of sepsis in pregnancy 2023. Aust N Z J Obstet Gynaecol. 2024 Jun 24. doi: 10.1111/ajo.13848.
* Yahya FB, Yousufuddin M, Gaston HJ, Fagbongbe E, Rangel Latuche LJ. Validating the performance of 3 sepsis screening tools in patients with clinical chorioamnionitis. AJOG Glob Rep. 2023 Oct 3;3(4):100271. doi: 10.1016/j.xagr.2023.100271. PMID: 37885969; PMCID: PMC10598707.
* Australian Commission on Safety and Quality in Health Care. [Lactate in the deteriorating patient and sepsis](https://www.safetyandquality.gov.au/publications-and-resources/resource-library/lactate-deteriorating-patient-sepsis-clinical-care-standard) Factsheet
* Australian Commission on Safety and Quality in Health Care. [Antimicrobial guidance for sepsis programs](https://www.safetyandquality.gov.au/publications-and-resources/resource-library/antimicrobial-guidance-sepsis-programs-sepsis-clinical-care-standard) Factsheet
* Australian Commission on Safety and Quality in Health Care. [Information for people with sepsis and their families (for adults)](https://www.safetyandquality.gov.au/publications-and-resources/resource-library/information-people-sepsis-and-their-families-adults-sepsis-clinical-care-standard) Factsheet.
* Australian Commission on Safety and Quality in Health Care.[National Consensus Statement: Essential elements for recognising and responding to acute physiological deterioration](https://www.safetyandquality.gov.au/our-work/recognising-and-responding-deterioration/recognising-and-responding-acute-physiological-deterioration/national-consensus-statement-essential-elements-recognising-and-responding-acute-physiological-deterioration)

**Citation**

1. To cite this document use: Safer Care Victoria. Maternal Sepsis Guideline [Internet]. Victoria: Maternity eHandbook; 2024 [cited xxxx] Available from: <https://www.safercare.vic.gov.au/clinical-guidance/maternity>

**Acknowledgement**

1. Safer Care Victoria would like to acknowledge Victoria’s four tertiary maternity services, the Royal Women’s, Mercy Hospital for Women, Joan Kirner Women’s and Children’s and Monash Women’s, for their significant contribution in the development of this guidance, as part of the Maternity and Neonatal eHandbook updating project 2023.

**For pregnant women and up to six weeks post-partum, including perinatal loss at any gestation, in any setting**

UR number ………………………………….....

Family name……………………………….……

Given name…………………………………..…

DOB………………………………………..…….

Address…………………………………..……...

**COMPLETE ALL FIELDS OR AFFIX LABEL HERE**

**RESPOND**

**Clinician name: Designation: Date:**

# MATERNAL SEPSIS PATHWAY



* **Fevers and rigors**
* **Neurological:** Altered conscious state, headache, neck stiffness, agitation
* **Peripheral perfusion:** Cool peripheries, delayed capillary refill, mottling
* **Chest:** Cough, shortness of breath
* **Abdomen:** Pain/tenderness, peritonism, diarrhoea, vomiting
* **Malodorous vaginal discharge**
* **Urine:** Dysuria, frequency, flank pain
* **Skin and soft tissues:** Cellulitis, mastitis
* **Wound erythema or discharge**
* **Line insertion sites:** Erythema, pain, swelling, discharge
* **And two or more of:** Temperature <36oC or > 38oC, respiratory rate >24 per minute for 15 minutes, HR 110 for > 15 minutes, WCC 15x109 or <4x109 or>10% immature neutrophils (bands)
* **OR** MAP < 65mmHg

**Diagnosis of sepsis should not be delayed while waiting for results A white cell count obtained within 24 hours can be used for initial screen**

**START TREATMENT PROMPTLY AND COMPLETE 1st DOSE OF ANTIBIOTICS WITHIN 60 MINUTES**

* **Oxygen:** Continuous oximetry. Maintain SpO2 >95%
* **IV access:** Insert 2X large bore peripheral cannulas
* **Investigations:** FBE, U&E’s, LFT’s, INR, APTT. Venous blood gas for lactate. 2 sets of anaerobic blood cultures
* **Observations:** HR and BP every 15 minutes for first hour then according to clinical picture. Document.
* **Antibiotics:** Promptly administer. See guidance - **Rapid antibiotic administration advice** (Table 3) plus tables 1-2
* **Source screening:**
* Midstream urine (MSU)/catheter specimen of urine (CSU) o high vaginal (HVS) / low vaginal (LVS) / endocervical swab for microscopy/culture/sensitivities (MCS)
* Sputum MCS & Chest x-ray
* Nasal/ throat swabs for extended panel respiratory viruses multiplex PCR, including COVID-19
* Wound swab for MCS
* Cultures from lumens of central lines
* Stool testing for faecal multiplex PCR including C. Difficile
* Breast milk MCS
* **Fluid management:** if systolic BP < 90 mmHg (or if lactate ≥ 2 mmol/L in the absence of labour)
* Stat fluid bolus of 500 ml of IV crystalloid, i.e. 0.9% sodium chloride; then further 500 ml STAT if required. Consider comorbidities, and monitor for fluid overload
* Escalate if no improvement in SBP after 1L of IV fluid.
* Insert IDC with hourly measure
* Monitor urine output hourly
* Escalate if urine output < 20 ml/hr
* **Fetal considerations:**
* Fetal surveillance if appropriate for gestation
* Expediate birth if chorioamnionitis is suspected
* Corticosteroids for preterm birth

**Escalate to senior staff, transfer to acute ward/ICU or higher maternity capability service. Call PIPER 1300 137 650.**

**ESCALATE**

**RECOGNISE**